DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights




DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

• Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks
• Held in Person pre-IND meeting with U.S. FDA to Discuss Plans for the Initiation of a U.S. Phase 2 DM199 Study in Preeclampsia
• AIS enrollment in ReMEDy2 Phase 2/3 Trial Nearing 50% of Target of 200 Patients for the Interim Analysis Expected in 2H 2026
• $55 million in Cash, Cash Equivalents and Investments, Anticipated Runway into 2H 2027
• Conference Call and Webcast on November 13 at 8:00 AM ET / 7:00 AM CT

MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction and acute ischemic stroke (AIS), today provided a business update and reported financial results for the third quarter ended September 30, 2025. Management will host a conference call on Thursday, November 13, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and third quarter 2025 financial results.

“We are pleased to see the completion of cohort 10 and the initiation of enrollments in the Part 1a expansion cohort in the ongoing Phase 2 investigators sponsored trial (IST) in preeclampsia,” said Rick Pauls, President and CEO of DiaMedica. “Regarding our development program for PE in the United States, we believe that we had a productive in-person pre-IND meeting with the FDA and are awaiting minutes from the meeting. We plan to provide an update after we receive the minutes. Enrollment in our ReMEDy2 Phase 2/3 trial in acute ischemic stroke continues to progress as we are nearing 50% of our interim target of 200 patients.”

Recent Corporate Highlights

Preeclampsia Phase 2 IST Clinical Development:

• Part 1a (PE, planned delivery within 72 hours): Completed cohort 10, showing results consistent with cohorts 6-9. Enrollment has advanced to an expansion cohort of up to 12 additional participants at the expected therapeutic dose level. Completion of this cohort is expected in 1H 2026.
• Part 1b (PE, planned delivery within 72 hours) and Part 2 (early onset PE with expectant management): based on clinical learnings from Part 1a, a protocol amendment for Parts 1b and 2 is being implemented to refine treatment regimens.
• Part 3 (fetal growth restriction): Screening for participants who do not have PE but have early onset fetal growth restriction is expected to begin in the coming weeks.

Preeclampsia in Person Pre-IND meeting with FDA:

• Given the complexities inherent in conducting clinical studies involving pregnant women, a very vulnerable patient group, DiaMedica requested a pre-IND meeting with the FDA to obtain feedback prior to submitting an IND application for preeclampsia.
• The FDA granted DiaMedica an in-person meeting, which has been recently held. DiaMedica plans to provide an update regarding the meeting once final meeting minutes are received.

Acute Ischemic Stroke ReMEDy2 Phase 2/3 Clinical Developments:

• Enrollment in DiaMedica’s Phase 2/3 ReMEDy2 (the ReMEDy2 trial – NCT065216) trial is nearing 50% of the target of 200 participants for the interim analysis.

Financial Results Highlights for the Third Quarter Ended September 30, 2025

• Cash Position and Runway – Cash and short-term investments were $55.3 million as of September 30, 2025, compared to $44.1 million as of December 31, 2024. The increase in combined cash and short-term investments is due to the net proceeds received from July private placement. Based on its current plans, DiaMedica anticipates its current cash and short-term investments will enable the Company to fund its planned clinical studies and support corporate operations into the second half of 2027.
• Cash Flows – Net cash used in operating activities for nine months ended September 30, 2025 was $21.3 million compared to $15.6 million for the same period in 2024. The increase in cash used in operating activities resulted primarily from the increased net loss in the nine months ended September 30, 2025 as compared with the prior year period, partially offset by changes in operating assets and liabilities during the current year period.
• Research and Development (R&D) – R&D expenses were $6.4 million and $17.9 million for the three and nine months ended September 30, 2025, respectively, up from $5.0 million and $12.6 million for the same periods in the prior year. The increase in both periods was due primarily to cost increases driven by the continued progress of the ReMEDy2 clinical trial, including its global expansion, progress with the Phase 2 IST in PE and the expansion of the clinical team during the current and prior year periods. These increases were partially offset by cost reductions related to manufacturing process development work performed and completed in the prior year period.
• General and Administrative (G&A) – G&A expenses were $2.6 million and $7.3 million for the three and nine months ended September 30, 2025, respectively, up from $1.9 million and $5.7 million for the three and nine months ended September 30, 2024, respectively. The increases in both periods resulted primarily from increased non-cash share-based compensation and increased personnel costs incurred in conjunction with expanding our team. Increases in investor relations, patent and professional fees also contributed to the increases in both periods.
• Net Loss – Net losses were $8.6 million and $24.0 million for the three and nine months ended September 30, 2025, respectively, up from $6.3 million and $16.5 million for the three and nine months ended September 30, 2024, respectively.

Conference Call and Webcast Information

DiaMedica Management will host a conference call and webcast to discuss its business update and third quarter 2025 financial results on Thursday, November 13, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on DiaMedica’s website, under investor relations – events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until November 20, 2025, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 9449322#.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expectations. When used in this press release, the words “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” or “will,” the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the Company’s expectations regarding the timing and nature of FDA meeting minutes, its application for an IND for the study of DM199 as a treatment for preeclampsia and fetal growth restriction and its conducting a Phase 2 trial in these indications; continued ReMEDy2 trial enrollment and timing of the interim analysis; anticipated clinical benefits and success of DM199 for the treatment of preeclampsia, fetal growth restriction and acute ischemic stroke; future R&D and G&A expenses and the Company’s projected cash runway. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to; the risk that existing preclinical and clinical data from DM199 as a treatment for preeclampsia may not be predictive of the results of ongoing or later clinical trials; DiaMedica’s plans to develop, obtain an IND for the clinical study of DM199 for PE and fetal growth restriction and ultimately regulatory approval for and commercialize its DM199 product candidate for the treatment of preeclampsia, fetal growth restriction and acute ischemic stroke, the timing of ReMEDy2 trial enrollment, regulatory applications and related filing and approval timelines; the expectation of steady or increased rates of enrollment in the ReMEDy2 trial will not continue to increase as anticipated; the possible occurrence of future adverse events associated with or unfavorable results from DiaMedica’s current trials and their potential to adversely effect current of future trials; the possibility of unfavorable results from DiaMedica’s ongoing or future clinical trials of DM199; and its expectations regarding the benefits of DM199; DiaMedica’s ability to conduct successful clinical testing of DM199 and within its anticipated parameters, site activations, enrollment numbers, costs and timeframes; the adaptive design of the ReMEDy2 trial and the possibility that the targeted enrollment and other aspects of the trial could change depending upon certain factors, including additional input from the FDA and the blinded interim analysis; the perceived benefits of DM199 over existing treatment options; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain shortages on DiaMedica’s business and clinical trials, including its ability to meet its site activation and enrollment goals; DiaMedica’s reliance on collaboration with third parties to conduct clinical trials; DiaMedica’s ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia and acute ischemic stroke and the risks identified under the heading “Risk Factors” in DiaMedica’s annual report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports, including the most recent quarterly report on Form 10-Q for the quarterly period ended September 30, 2025. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, including the securities laws of the United States, we do not intend to update any forward-looking statements to conform these statements to actual results or to changes in our expectations.

Contacts

Contact:
Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

For Investor Inquiries:
Mike Moyer

Managing Director, LifeSci Advisors, LLC

Phone: (617) 308-4306

mmoyer@lifesciadvisors.com

Media Contact:
Madelin Hawtin

LifeSci Communications

mhawtin@lifescicomms.com

HealthWarehouse.com Reports Results for Third Quarter 2025




HealthWarehouse.com Reports Results for Third Quarter 2025

Reports 7% decline in sales due to slowing DTC sales and shifts in GLP-1 market

CINCINNATI–(BUSINESS WIRE)–HealthWarehouse.com, Inc. (OTCQB:HEWA) announced today that its net sales for the third quarter ended September 30, 2025, totaled $8.4 million, a 7% decrease from the quarter ended September 30, 2024. The Company reported a net loss of $72,000 and Adjusted EBITDA of $343,000 for the quarter. Year to date, the Company reported sales of $39.1 million, a 97% increase over the prior year, net income of $334,000 and Adjusted EBITDA of $1.4 million.

HealthWarehouse.com, a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (NABP). HealthWarehouse.com provides a platform focused on increasing access to and reducing costs of healthcare products for consumers and business partners nationwide.

Joseph Peters, President and CEO, commented, “As anticipated, our sales growth for the quarter slowed as our sales of compounded versions of certain GLP-1 prescription medications declined. The FDA had temporarily approved sales of compounded GLP-1s during market shortages of branded versions. Despite the slowing of growth, we generated positive cash flow and we built up our cash balances during the quarter, proving the economic scalability of our business model. Additionally, we are optimistic about new product launches that will allow us to continue to serve longstanding partners. These products diversify our catalog following the removal of certain medications from the shortage list.”

HealthWarehouse.com continues to invest in proprietary technology to remain at the forefront of new developments and offerings in the world of healthcare, focusing on patient experience, operational efficiency, and scalability.

“We remain optimistic about our future as our partners have diversified their offerings and we have a strong pipeline of new opportunities for our partner service business. In addition, we are well equipped to help manufacturers launch direct-to-patient programs and are eager to develop new opportunities in that market,” added Peters. “We have established ourselves as a reliable service provider for high volume partners and we have shown our expertise in processing orders that require cold-chain shipping services. I appreciate the effort put forth by our team of dedicated employees, as they continue to provide world class service to our customers.”

Overview of Results for Three and Nine Months Ended September 30, 2025

Net Sales: Total net sales for the three and nine months ended September 30, 2025, were $8.4 million and $39.1 million, respectively, a decrease of $612,000 (6.8%) for the three-month period and an increase of $19.2 million (96.6%) for the nine-month period versus the same periods in 2024.

Prescription sales were $7.7 million and $37.1 million for the three and nine months ended September 30, 2025, respectively, a decrease of $655,000 (7.9%) and an increase of $19.2 million (107.0%), respectively, compared with the same periods in 2024. The decrease in sales for the three-month period was due to a $531,000 decline in direct-to-consumer prescription business and a $28,000 decline in the partner services business. The increase in prescription sales for the nine-month period was due to growth in partner services revenue of $21.4 million, offset by a $2.2 million decline in the direct-to-consumer prescription business.

Sales of over-the-counter products were $689,000 and $1.8 million for the three and nine months ended September 30, 2025, respectively, an increase of $67,000 (10.8%) and $74,000 (4.2%), respectively, over the same periods in 2024, primarily due to increases in marketplace sales.

Gross Profit: Gross profit for the three and nine months ended September 30, 2025, was $3.6 million and $13.3 million, respectively, representing a decrease of $194,000 for the three-month period and an increase of $3.6 million for the nine-month period compared with the same periods in 2024. The decrease in the three-month period was the result of lower sales offset by improved gross margin. The increase in the nine-month period was the result of higher sales offset by lower margins on our partner services prescription business. Gross margin percentages were 42.8% and 34.0% for the three and nine months ended September 30, 2025, respectively, which were 0.8 percentage point higher and 14.9 percentage points lower, respectively, versus prior-year periods. The reduction was primarily due to lower margins in the Partner Services prescription businesses.

Operating Expenses: Selling, general and administrative expenses were $3.6 million and $12.8 million for the three and nine months ended September 30, 2025, respectively, which were increases of $5,000 (0.1%) and $2.8 million (27.6%), respectively, compared to the same periods in 2024. Expenses for the three-month period included increases in legal, rent, advertising, software and engineering, and salaries expenses, offset by decreases in shipping and shipping supplies, and credit card expenses. Expense increases for the nine-month period included increases in shipping and shipping supplies, salaries primarily related to higher direct pharmacy labor, legal, advertising and rent, which were offset by decreases in credit card fees and employee benefits expenses.

Net Income (Loss) and Adjusted EBITDA: The Company reported net loss of $72,000 and net income of $334,000 for the three and nine months ended September 30, 2025, respectively, compared with net income of $74,000 and net loss of $522,000, respectively, for the same periods in 2024.

Earnings before interest, taxes, depreciation and amortization (“EBITDA”), as adjusted for stock-based compensation and certain non-recurring charges (“Adjusted EBITDA”), were $343,000 for the three months and $1.4 million for the nine months ended September 30, 2025. That compares with Adjusted EBITDA of $405,000 and $495,000, respectively, for the three and nine months ended September 30, 2024. EBITDA and Adjusted EBITDA are non-GAAP financial measures. Definitions of these non-GAAP terms and a reconciliation to GAAP measures are provided below.

Use of Non-GAAP Financial Measures

HealthWarehouse.com, Inc. (the “Company”) prepares its consolidated financial statements in accordance with the United States generally accepted accounting principles (“GAAP”). In addition to disclosing financial results prepared in accordance with GAAP, the Company discloses information regarding EBITDA and Adjusted EBITDA, which are commonly used. In addition to adjusting net income or net loss to exclude interest, taxes, depreciation and amortization, including amortization of right of use lease asset, (“EBITDA”), Adjusted EBITDA also excludes stock-based compensation, and certain nonrecurring charges. EBITDA and Adjusted EBITDA are not measures of performance defined in accordance with GAAP. However, Adjusted EBITDA is used internally in planning and evaluating the Company`s performance. Accordingly, management believes that disclosure of this metric offers lenders and other shareholders an additional view of the Company`s operations that, when coupled with GAAP results, provides a more complete understanding of the Company’s financial results.

Adjusted EBITDA should not be considered as an alternative to net income, net loss or to net cash provided by or used in operating activities as a measure of operating results or of liquidity. It may not be comparable to similarly titled measures used by other companies, and it excludes financial information that some may consider important in evaluating the Company`s performance.

Reconciliation of Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP)

About HealthWarehouse.com

HealthWarehouse.com, Inc. (OTCQB: HEWA), a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (“NABP”). HealthWarehouse.com provides a platform focused on increasing access and reducing costs of healthcare products for consumers and business partners nationwide. Based in Florence, Kentucky, the Company operates America’s Leading Online Pharmacy and is a pioneer in affordable healthcare. As one of the first National Association of Boards of Pharmacy Approved Digital Pharmacies, HealthWarehouse.com services the mission of providing affordable healthcare and incredible patient services to help Americans. Learn more at www.HealthWarehouse.com

Forward-Looking Statements

This announcement and the information incorporated by reference herein contain “forward-looking statements” as defined in federal securities laws, including but not limited to Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which statements are based on our current expectations, estimates, forecasts and projections. Statements that are not historical facts, including statements about the beliefs, expectations and future plans and strategies of the Company, are forward-looking statements. Actual results may differ materially from those expressed in forward looking statements or in management’s expectations. Important factors which could cause or contribute to actual results being materially and adversely different from those described or implied by forward looking statements include, among others, risks related to competition, management of growth, access to sufficient capital to fund our business and our growth, new products, services and technologies, potential fluctuations in operating results, international expansion, outcomes of legal proceedings and claims, fulfillment center optimization, seasonality, commercial agreements, acquisitions and strategic transactions, foreign exchange rates, system interruption, cyber-attacks, access to sufficient inventory, government regulation and taxation and fraud. More information about factors that potentially could affect HealthWarehouse.com’s financial results is included in HealthWarehouse.com’s audited Annual Reports and Quarterly Reports available at otcmarkets.com and prior filings with the Securities and Exchange Commission.

Contacts

Dan Seliga, Chief Financial Officer, (800) 748-7001

Shift Bioscience Publishes Improved Metric Calibration Framework for Robust Genetic Perturbation Modeling Using AI Virtual Cells




Shift Bioscience Publishes Improved Metric Calibration Framework for Robust Genetic Perturbation Modeling Using AI Virtual Cells

• AI virtual cells outperform key baselines on well-calibrated metrics, challenging prior reports of poor model performance
• Foundational research reinforces the use of virtual cell models to accelerate target identification pipelines

CAMBRIDGE, England–(BUSINESS WIRE)–Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to end the morbidity and mortality of aging, today announced the release of new research detailing an improved framework for evaluating benchmark metric calibration in virtual cell models¹. Using well-calibrated metrics, the study demonstrates that virtual cell models consistently outperform key baselines, providing valuable and actionable biological insights to accelerate target identification pipelines.

Genetic perturbation response models are a subset of AI virtual cells used to predict how cells will respond to various genetic alterations, including up- and down-regulation of genes. These models are a valuable tool to augment target identification pipelines, providing a rapidly scalable, in silico solution to identify promising genetic targets without the time and resource requirements of wet lab experiments. However, recently published papers have questioned the utility of these models to correctly identify gene targets, noting concerns that virtual cell models fail to outperform simple, uninformative baselines in some experiments.

In this latest study from Shift Bioscience, the team demonstrated that incidents of poor model performance largely reflect metric miscalibration, with commonly-used metrics routinely failing to distinguish robust predictions from uninformative ones, particularly in datasets with weaker perturbations. Building on this finding, the team developed an improved framework for metric calibration. Using 14 perturb-seq datasets, the team identified several rank-based and DEG (Differentially Expressed Gene)-aware metrics that are well-calibrated across datasets.

Virtual cell models evaluated using these well-calibrated metrics were able to consistently outperform uninformative mean, control and linear baselines, providing clear evidence that virtual cell models can distinguish biologically significant signals when appropriate calibration is applied. These results challenge prior reports that genetic perturbation models do not work, and suggest that AI Virtual Cells can be effectively applied for target discovery.

Henry Miller, Ph.D., Head of Machine Learning, Shift Bioscience, commented: “This latest research from our talented team provides clear evidence that the reports of poor performance in AI virtual cells is largely due to limitations of metrics, not due to issues with the models. We showed that when models are evaluated on well-calibrated metrics, they perform quite well and consistently outperform key baselines. We believe that this work opens the door to more widespread use of virtual cells and reinforces our confidence in the virtual cell models that are helping to drive our target identification program for cell rejuvenation.”

1. Deep Learning-Based Genetic Perturbation Models Do Outperform Uninformative Baselines on Well-Calibrated Metrics

Contacts

Jake Brown

jake.brown@zymecommunications.com

Qorium Secures €22m Investment to Accelerate Cultivated Leather Commercialisation




Qorium Secures €22m Investment to Accelerate Cultivated Leather Commercialisation

Invest-NL, LIOF and several private investors join Brightlands Venture Partners and Sofinnova Partners in supporting the Dutch biotech firm’s growth

MAASTRICHT, Netherlands–(BUSINESS WIRE)–Qorium, the Dutch biotechnology company pioneering cultivated leather, today announced it has secured a €22 million investment from Invest-NL and LIOF alongside existing investors Brightlands Venture Partners and Sofinnova Partners. An influential group of high net worth individuals have also participated in the round while the Invest-NL investment is made under the InvestEU guarantee scheme of the European Commission.

The cultivated leather market is projected to grow rapidly as demand increases for consistent and high-quality real leather. Qorium’s technology produces beautiful, uniform real leather from a few animal cells, eliminating the need for livestock farming while improving final leather products, reducing production waste and significantly reducing the environmental impact vs. animal-derived leather.

This latest round builds on €8 million in seed funding and marks another important milestone in Qorium’s journey from scientific breakthrough to commercial reality. The company is successfully producing sustainable real leather, is installing new bioreactor systems at its Maastricht facilities, and has established several commercial partnerships. With this Series A investment, Qorium is poised to scale production.

“This investment is a powerful vote of confidence in our mission to transform the leather industry,” says Qorium CEO Michael Newton. “By combining cutting-edge science with deep leather expertise and sustainable practices, we are creating real leather that offers better performance than traditional animal-derived leather, without the environmental and ethical costs. With Invest-NL, LIOF, and others now on board, we can take the next steps towards reinventing real leather and bring it to market at scale.”

“At Invest-NL, we invest in technologies that drive systemic change. Qorium’s leather is a breakthrough innovation that can transform one of the world’s most polluting industries,” says Lisette Kersting-van der Boog from Invest-NL. “By producing real leather without livestock, Qorium shows how biotechnology can build a more sustainable materials system. We are proud to support this Dutch frontrunner in scaling their impact.”

Guillaume Baxter, Partner at Sofinnova Partners, echoes the sentiment: “We’ve been on this journey with Qorium from the start, backing both the science of Dr. Mark Post and the deep leather experience of Rutger Ploem. This investment reflects Qorium’s impressive progress to date and our strong belief in the economic and sustainability potential of its leather. We are confident that this momentum will only continue.”

This latest round of funding strengthens Qorium’s position as a frontrunner in the global shift towards sustainable materials and underscores growing investor confidence in the field of cultivated leather. Qorium will appoint a new director to its board in the coming weeks.

To learn more about Qorium, visit qorium.com

Contacts

For media enquiries:
Sarah Taylor

Sarah@stbailey.com

Aqemia to Participate in the Jefferies Global Healthcare Conference 2025




Aqemia to Participate in the Jefferies Global Healthcare Conference 2025

LONDON–(BUSINESS WIRE)–Aqemia, a pioneering TechBio company combining generative AI and quantum-inspired physics to invent drugs, announces that Maximilien Levesque, CEO and co-founder, and Théa Vu-Bignand, VP Finance, will attend the Jefferies Global Healthcare Conference, taking place in London from November 17 – 20, 2025.

With its physics-based generative AI platform for therapeutic molecule invention, QEMI, Aqemia can design novel drug candidates in a repeatable, frugal, and scalable way, with the ambition to deliver new therapies faster to patients who currently lack effective treatments, particularly in oncology. In this perspective, Aqemia remains focused on building value through its internal preclinical pipeline while forging partnerships that validate its platform and scientific edge.

About Aqemia

Aqemia is a drug invention company dedicated to creating novel molecules to address unmet medical needs. Its proprietary QEMI platform combines more than 12 years of physics-based research with state-of-the-art generative AI, enabling the launch of preclinical programs without relying on experimental data and accelerating discovery from day one. Aqemia’s portfolio spans oncology, immunology, neurology, and cardiology, and includes both wholly owned programs and partnered programs with leading pharmaceutical companies, such as a multi-year, $150M strategic collaboration with Sanofi. The company’s most advanced preclinical programs are currently undergoing in vivo optimization. Headquartered in Paris with an office in London, Aqemia has raised over $100 million since its inception.

Contacts

Press
Orianne Bornand – Head of Communications

+33 6 10 04 32 80 I orianne.bornand@aqemia.com

Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth




Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth

MONTPELLIER, France–(BUSINESS WIRE)–Medincell, a clinical-stage pharmaceutical company pioneering long-acting injectable therapies, today announced the expanded role of Dr Grace Kim, Chief Strategy Officer, U.S. Finance.

Over the past two years, Grace has played a key and successful role within the Medincell team, with the initial and decisive shaping of the company’s US capital growth strategy and advancing cross-border initiatives.

As Medincell enters a pivotal growth phase, Dr. Kim will build on this foundation to lead and execute the next stages of company’s U.S. capital growth strategy, driving long-term value for patients, partners, and investors.

About Dr Grace Kim

Dr Grace Kim serves as Medincell’s Chief Strategy Officer, U.S. Finance, acting as an execution partner for the company’s U.S. capital strategy and global expansion. Dr Grace Kim has two decades’ experience in Capital Markets, Corporate Strategy, and Investment Banking. Grace previously served as Chief Strategy Officer of Molecular Templates and CEO of SNO Bio. She also leads a longstanding NY biotech advisory. With a $10 billion track record, Grace has driven value for >160 companies including BeiGene/BeOne, Biomarin, Cullinan Therapeutics, Zai Lab, Aimmune/Nestle, Immunity Bio, and Umoja Biopharma. Grace’s training in medicinal chemistry and pharmacology includes studies at the University of Chicago, a doctorate from the University of Florida, and MBA studies at Wharton. She is published in Nature Clinical Oncology and holds an adjunct faculty position at Columbia University. Grace is also a Board Advisor for Life Science Cares.

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.

www.medincell.com

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG

david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Chief Strategy Officer, U.S. Finance

grace.kim@medincell.com / +1 (646) 991-4023

Nicolas Mérigeau / Arthur Rouillé
Media Relations

Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier / Alban Dufumier
Investor Relations France

Medincell@newcap.eu / +33 (0)1 44 71 94 94

Prescott’s Med Announces Acquisition of Tenacore – Strengthening Its Position as a Leader in Surgical Suite and Specialty Biomed Solutions




Prescott’s Med Announces Acquisition of Tenacore – Strengthening Its Position as a Leader in Surgical Suite and Specialty Biomed Solutions

MONUMENT, Colo.–(BUSINESS WIRE)–Prescott’s Med is thrilled to announce a major milestone in the company’s ongoing mission to be the trusted leader in surgical suite and specialty biomed solutions, supporting healthcare biomed strategies. Prescott’s Med has acquired Tenacore, based in Costa Mesa, CA, a recognized leader in depot-based medical device repair, parts, and technical support.

Established in 2000, Tenacore has a strong reputation for delivering a wide range of depot repair services, medical equipment, and parts. With a “Quality at the Core” focus, Tenacore is a trusted industry partner for hospitals, ISOs, and in-house biomedical departments.

“This strategic move represents far more than an acquisition by bringing together industry-leading specialists to create an unparalleled, nationwide depot partner for biomedical teams,” said Brian Straeb, Chief Executive Officer of Prescott’s Med. “By unifying our expertise, infrastructure, and service excellence, we’re delivering a new standard of reliability and responsiveness for our customers across the country.”

This acquisition reinforces the commitment of Prescott’s Med’s as a true partner to biomedical teams. The company is building its support service operations to enable healthcare providers’ chosen biomed service solutions. The addition of Tenacore increases Prescott’s Med’s already robust depot capabilities. Together, the companies have a nationwide network of depot locations, an expansive inventory to support repair services, and expanded service capabilities—including infusion pumps, patient monitors, blenders and regulators, defibrillators, ESUs, parts, rentals, and more.

About Prescott’s Med

Prescott’s Med continues to grow both organically and inorganically to support specialty biomed and provide field and depot service solutions. Prescott’s Med includes several specialized service divisions, including Surgical Microscopes (Prescott’s Inc.), Anesthesia (Heartland Medical), Sterilizers and Washers (PMM & Washer Solutions), Infusion Pumps (Adepto Medical), and Patient Monitors (Pioneer Biomedical). Prescott’s Med tailors its services to match your facility’s unique operational requirements. Our flexible service options ensure that you receive exactly what you need, when you need it, with the peace of mind that comes from working with a trusted partner. www.prescottsmed.com

For media inquiries, interviews, or additional information, please contact Prescott’s Med Communications Team at communications@prescottsmed.com or reach out to Christina O’Dell directly at 844-498-1927. We welcome your questions and look forward to sharing more about this exciting milestone.

Contacts

communications@prescottsmed.com

Christina O’Dell

844-498-1927

Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms




Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms

INCHEON, Korea–(BUSINESS WIRE)–#EpisNexLab–Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms.

Epis NexLab will focus on transforming highly scalable core technologies into platforms for the discovery of diverse new drug candidates, including license-out or joint development with global pharmaceutical companies. As part of its search for new business opportunities, the company plans to explore various new modalities including amino acid or peptide conjugate platform technologies.

Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to his current role as the Executive Vice President and Head of Research and Early Development at Samsung Bioepis. He will also serve on the board of directors of Samsung Epis Holdings as a non-executive director.

“Building on the R&D expertise accumulated through years of developing quality-assured biologics at Samsung Bioepis, we will focus on securing next-generation biotechnology platforms that can drive sustainable growth for the new company beyond the biosimilar business,” said Peter Seongwon Hong, CEO of Epis NexLab. “Our long-term goal is to become a leading biotechnology company in next-generation therapeutic technologies and we will be relentless in our efforts to drive this growth, through innovative research and development and strategic investment.”

Epis NexLab

Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab will focus on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Samsung Epis Holdings and Epis NexLab, please visit: www.samsungepisholdings.com

Contacts

MEDIA CONTACT – Samsung Bioepis
Anna Nayun Kim, nayun86.kim@samsung.com
Yoon Kim, yoon1.kim@samsung.com

Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR




Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the “District Court”) has denied a request by the U.S. Federal Trade Commission (the “FTC”) and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR LLC (“GTCR”) from consummating the proposed acquisition of the Company by an affiliate of GTCR (the “Merger”).

Consummation of the Merger remains subject to a Temporary Restraining Order under which the parties to the Merger agree not to consummate the Merger prior to 5:00 p.m. Central time on Monday, November 17. It also remains subject to the satisfaction or waiver of closing conditions set forth in the agreement related to the Merger (the “merger agreement”), including (1) the absence of any injunction or other legal restraint or prohibition that would prevent or prohibit the consummation of the Merger, (2) the absence of a “Company Material Adverse Effect” (as defined in the merger agreement) with respect to the Company and (3) other customary closing conditions.

“The District Court’s ruling is a significant step toward being able to complete the Merger, which we continue to believe will position the Company to continue to deliver compelling benefits for physicians, patients and customers going forward,” said Gary Maharaj, President and CEO of Surmodics, Inc. “I would like to extend a heartfelt thanks to our legal advisors for their hard work in helping Surmodics to defend this proposed transaction in court, and to our employees for their unwavering dedication to maintaining our excellent operating performance.”

About Surmodics, Inc.

Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the Company makes with the Securities and Exchange Commission (the “SEC”).

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements regarding completion of the Merger, the Company’s belief that the Merger will position the Company to continue to deliver compelling benefits for physicians, patients and customers, when the pending Merger will be consummated, if at all, and its potential consequences, including the expected financing of the Merger, the expectation that the Company will be privately held after the Merger, and conditions for consummation of the Merger, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Contacts

Surmodics Investor Inquiries:

Jack Powell, Investor Relations

ir@surmodics.com

Surmodics Public Relations Inquiries:

pr@surmodics.com

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants




Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has agreed to sell by way of an underwritten offering 10,815,000 shares of its common stock and accompanying warrants to purchase up to 5,407,500 shares of common stock at a combined price of $6.14 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,400,000 shares of its common stock and accompanying one-half of a warrant to purchase up to 700,000 shares of common stock at a combined price of $6.139995, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Precision from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. Each whole warrant has an exercise price of $7.25 per share, is exercisable immediately and will expire five years following the date of issuance. The deal includes participation from new and existing investors, including Aberdeen Investments, Bleichroeder LP, Driehaus Capital Management, Empery Asset Management LP, Lynx1 Capital Management, Octagon Capital, Readout Capital, Sphera Funds Management, Stonepine Capital Management, as well as other leading life sciences investors.

The offering is expected to close on or about November 12, 2025, subject to customary closing conditions. All shares of common stock, pre-funded warrants and accompanying one-half of a warrant to purchase shares of common stock to be sold in the offering will be sold by Precision. Precision intends to use the net proceeds of the offering to help fund ongoing and planned research and development, and for working capital and general corporate purposes.

Guggenheim Securities is acting as sole book-running manager for the offering.

The securities described above were offered by means of a prospectus supplement dated November 10, 2025, and accompanying prospectus dated June 15, 2023, forming part of Precision’s effective shelf registration statement (File No. 333-272540). The prospectus supplement and accompanying prospectus relating to this offering will be filed with the U.S. Securities and Exchange Commission (the “SEC”) and will be available on the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus may also be obtained, when available, by contacting: Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8^th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in this offering in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Precision BioSciences, Inc.

Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Precision’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist.

Forward-Looking Statements

Certain statements contained in this press release, including those relating to the timing and size of the offering, the anticipated total gross proceeds from the offering and other statements relating to the proposed offering, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed offering, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed offering, the completion of the offering on the anticipated terms or at all, general economic conditions and other risks identified from time to time in the reports Precision files with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and the prospectus supplement and accompanying prospectus related to the proposed offering to be filed with the SEC, which are or will be available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and Precision undertakes no obligation to update or revise any of the statements. Precision’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts

Investor and Media Contact:
Naresh Tanna

Vice President of Investor Relations

Naresh.tanna@precisionbiosciences.com